FindTrial
Sign In

Efficacy of topical Unani formulation in the pateints of Tinea Corporis: An open-label, randomised controlled trial

Therapeutic efficacy of a topical unani formulation containing Sirka and Samgh-i-Arabi in the management of Quba Khabith (Tinea Corporis): An open labeled, randomised clinical trial with standard control - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082632
Enrollment
52
Registered
2025-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Semi-solid unani formulation: Compound Test drug formulation in semi-solid form with two main ingredients, Sirka, and Samgh-i-Arabi, for topical application. Both ingredients, Sirka and

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Quba Khabith (tinea corporis) 2. Patients in the age group of 18 to 60 irrespective of gender 3. KOH (potassium hydroxide) positive 4. Patients willing to sign written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients below the age of 18 years and above 60 years 2. History of drug-induced allergy 3. Pregnant or breastfeeding mothers 4. Active case of malignancy 5. Patients having diabetes mellitus or cardiovascular or renal diseases. 6. Unwillingness or inability to fulfill the protocol or patients who fail to consent. 7. KOH (potassium hydroxide) negative

Design outcomes

Primary

MeasureTime frame
1. Typical Lesion with itching, Scaling, Erythema, Papules, Vesicles 2. KOH (potassium hydroxide) Negative 3. TSSS (Total sign and symptoms score)Timepoint: 7th, 14th, 21st, and 28th day of the study. KOH will be assessed on 0th and 29th (before and after)—

Secondary

MeasureTime frame
1. DLQI (Dermatology life quality index) 2. Pre and Post photograph of the lesion siteTimepoint: 0th and 29th (Before and After)—

Countries

India

Contacts

Public ContactDr Adnan Ali

Regional Research Institute of Unani Medicine (RRIUM), Srinagar

drasgarnazir11@gmail.com6005516889

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026